“As COVID-19 continues to spread globally, healthcare providers are working diligently to treat soaring numbers of patients at a time when there are too few ventilators to provide care,” said Matt Moran, Philips Australia and New Zealand Managing Director. “Philips is responding to this pressing global need by quickly scaling production of the new Philips Respironics E30 ventilator with the needs of healthcare workers and COVID-19 patients in mind while also complying with medical device quality standards. Our hope is that this solution will help to free-up ICU ventilators for use in treating the most severe patients.”
The Philips Respironics E30 Ventilator is provided globally for use under local emergency use authorizations, such as the FDA Emergency Use Authorization for ventilators, for use in relation to COVID-19, and waiver of CE marking, which authorize its use for the duration of the COVID-19 public health emergency, unless terminated or revoked (after which the products may no longer be used).
For more information on the Philips Respironics E30 ventilator, please click here.